Connect your AI

Innoviva, Inc. INVA Equity Method Income

Equity Method Income at other companies

Royalty PharmaRPRX

$21.76M+238%

Option Care Health, Inc.OPCH

$1.69M-2.3%

Other financials

Income statement

Revenue$98.0M+10.6%

Gross profit$75.8M+3.4%

Operating income$38.2M-7.9%

Net income$186.6M+501%

EPS (diluted)$2.22+400%

Balance sheet

Cash & equivalents$603.1M+89.0%

Total debt$269.4M-40.3%

Total equity$1.3B—

Total assets$1.8B+46.4%

Cash flow

Operating cash flow$35.3M-27.4%

CapEx$492.0K—

Free cash flow$34.8M-28.4%

Valuation

Market cap$1.74B+51.8%

Enterprise value$1.41B+9.7%

P/E3.5×—

P/S4.2×+1.0×

Profitability

Gross margin73.7%-9.9pp

Operating margin38.1%-11.2pp

Net margin119.9%+107pp

FCF margin54.1%+5.3pp

Returns & leverage

Return on equity29.1%—

Debt / equity0.2×—

Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s equity method income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Innoviva, Inc.'s equity method income?: Innoviva, Inc. (INVA) reported equity method income of $157.65M in Q1 2026.
How has Innoviva, Inc.'s equity method income changed year-over-year?: Innoviva, Inc.'s equity method income increased by 1263.6% year-over-year, from -$13.55M to $157.65M.
What is the long-term trend for Innoviva, Inc.'s equity method income?: Over 4 years (2021 to 2025), Innoviva, Inc.'s equity method income has grown at a 13.8% compound annual growth rate (CAGR), from $84.39M to $141.43M.
What does equity method income mean?: The company's proportional share of net income or loss from unconsolidated affiliates and joint ventures accounted for under the equity method.